Engineered nanomedicine for myeloma and bone microenvironment targeting

Area of Science:

• Biomaterials Science
• Nanotechnology
• Oncology

Background:

• Bone is a common site for cancer metastasis, posing treatment challenges due to poor drug delivery and resistance.
• Targeting bone cancers requires overcoming issues of drug availability and the bone marrow microenvironment's protective effects.

Purpose of the Study:

• To engineer bone-homing polymeric nanoparticles (NPs) for targeted delivery of therapeutics to bone.
• To improve drug concentration at the tumor site and reduce systemic toxicity for bone metastasis treatment.

Main Methods:

• Developed poly(D,L-lactic-co-glycolic acid) (PLGA)-based nanoparticles conjugated with alendronate (Ald) for bone targeting.
• Assessed bone-binding using hydroxyapatite assays and ex vivo imaging.
• Evaluated in vivo biodistribution, drug loading, release profiles, and therapeutic efficacy in multiple myeloma mouse models using bortezomib-loaded NPs.

Main Results:

• Targeted Ald-PEG-PLGA NPs demonstrated superior bone retention and accumulation compared to non-targeted NPs.
• Alendronate-conjugated bortezomib NPs (Ald-Bort-NPs) significantly increased survival and reduced tumor burden in multiple myeloma models.
• Bortezomib pretreatment also improved bone strength and volume, indicating microenvironment modification.

Conclusions:

• Bone-homing nanoparticles offer a promising strategy for targeted cancer therapy in bone.
• This approach enhances drug delivery, improves therapeutic outcomes, and potentially mitigates bone damage in metastatic cancers like multiple myeloma.